Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children:

A Randomised Controlled Crossover Trial

Nina-Francesca Parrella[1]*, Aron T. Hill[1], Peter G. Enticott[1], Tanita Botha[2], Sarah Catchlove[3],

Luke Downey[4], Talitha C. Ford[1,4]

[1] School of Psychology, Deakin University, Burwood, Australia

[2] Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Australia

[3] Eastern Health Clinical School, Monash University, Melbourne, Australia

[4] Centre for Mental Health & Brain Sciences, School of Health Sciences, Swinburne University of Technology, Melbourne, Australia

*Corresponding author: Nina-Francesca Parrella, n.parrella@deakin.edu.au

Ethics Approval Statement
This study received ethics approval from the Deakin University Human Research Ethics Committee (DUHREC 2020-071) prior to enrolment of the first participant.

Patient Consent Statement
Written informed consent was obtained from the parents or guardians of all participants. Assent was obtained from participants when appropriate.

Clinical Trial Registration
This trial was prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12622000437763).

Funding Statement
This study received no external funding. In-kind support was provided by Medigrowth in the form of investigational product. No cash or other financial support was received from Medigrowth.

Conflict of Interest Disclosure
All authors declare no biomedical financial interests or potential conflicts of interest. This study is an investigator-initiated trial, and none of the authors have any commercial interest in Medigrowth.

Data Availability Statement
The datasets generated and analysed during the current study are available from the corresponding author upon reasonable request.

Permission to Reproduce Material
No third-party copyrighted material was reproduced in this manuscript.

Lay Summary

This study examined whether taking CBD oil could improve social outcomes for autistic children. While no significant changes were seen in overall social responsiveness, CBD led to improvements in specific social behaviours, reduced anxiety, and lowered parental stress. The treatment was generally well tolerated, though a few children experienced mild side effects. These findings suggest potential benefits of CBD for some autism-related symptoms, but larger studies are needed to confirm effectiveness.

Abstract

Cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, has garnered increasing attention as a potential pharmacological therapeutic for autism. We conducted a randomised, double-blind, placebo-controlled, crossover trial to understand whether oral CBD oil containing terpenes can improve outcomes in autistic children. Twenty-nine children (18 male), aged 5 to 12 years (M=9.62 years, SD=2.05), diagnosed with autism spectrum disorder, completed the study. Participants received weight-based dosing of CBD oil (10 mg/kg/day) or matched placebo oil over two 12-week intervention periods (crossover), separated by an 8-week washout period. Outcome measures included the Social Responsiveness Scale-2 (SRS-2; primary outcome), PROMIS Social Relating, Anxiety, and Sleep, Developmental Behaviour Checklist-2 (DBC-2), Vineland 3, and Autism Parenting Stress Index (APSI; secondary outcomes). There was no significant effect observed for the primary outcome measure (SRS-2) for CBD oil relative to placebo oil after 12 weeks, (β=-11.15, SE=7.19, p=.125). Significant improvements were observed in secondary measures of social functioning, including DBC-2 Social Relating (β=-2.35, SE=0.92, $p_{(adj)}$=.024), as well as reduced anxiety on the DBC-2 subscale (β=-3.20, SE=0.94, $p_{(adj)}$=.002) and lower parental stress (APSI; β=-4.63, SE=2.26, $p_{(adj)}$=.044). Safety and tolerability data indicated that two children experienced gastrointestinal discomfort while taking CBD. Findings from this pilot trial suggest that, while CBD combined with terpenes did not improve the primary outcome of social responsiveness, it may hold potential in addressing certain autism-related difficulties, particularly anxiety and social difficulties. Further research with larger sample sizes is needed to fully evaluate the efficacy and safety of CBD for autistic children.

Introduction

Cannabidiol (CBD) is a non-addictive and non-intoxicating compound derived from the *Cannabis sativa (C. sativa)* L. plant (VanDolah et al., 2019). It is recognised for its therapeutic potential in various somatic, psychiatric, and neurodevelopmental conditions (Larsen & Shahinas, 2020), including autism (Aran et al., 2021). CBD has multiple identified pharmacological properties, which include anti-inflammatory (Weiss et al., 2008), anxiolytic (Bergamaschi et al., 2011), and neuroprotective effects (VanDolah et al., 2019). The past six years have witnessed a notable increase in the utilisation of CBD for psychiatry-related conditions (Cairns et al., 2023), accompanied by a surge in research efforts aimed at exploring its potential therapeutic benefits (Abi-Jaoude et al., 2022; Cooper et al., 2016). Preclinical research in animal models first implicated the endocannabinoid system (ECS) in autism-like behaviours, which led to subsequent investigations into the potential of CBD to modulate core autism symptoms (Zamberletti et al., 2017). Recent research suggests CBD treatment may be effective in addressing behavioural and communicative difficulties in autistic children (Aran et al., 2021; Silva Junior et al., 2024), which raises the possibility that modulation of the endocannabinoid system (ECS) could be a promising target for addressing core symptoms of autism. The complex pharmacodynamics of CBD suggest that its therapeutic effects involve multiple molecular targets and mechanisms, with modulation of the ECS central to current research.

The ECS, a neuro-modulatory system involved in emotional regulation and social responsiveness, has emerged as a significant factor in the pathophysiology of autism (Karhson et al., 2016; Wei et al., 2015, 2016). While still in preliminary stages, extant research suggests that dysregulated cannabinoid signalling may underlie autism symptomatology, specifically in the social domain (Karhson et al., 2016, 2018). Pharmacological therapeutics targeting the ECS may offer support for autistic people

(Bottema-Beutel et al., 2021; Kenny et al., 2016), particularly those with social communication difficulties (Karhson et al., 2016; Wei et al., 2016). There is growing scientific interest in CBD as a potential therapeutic for neurodevelopmental disorders due to its non-intoxicating nature and robust safety profile (Chin et al., 2020; Lattanzi et al., 2018). Several studies have investigated CBD in autistic adults and children to target associated symptoms, such as hyperactivity, sleep, and anxiety (Aran et al., 2018; Barchel et al., 2019; Parrella et al., 2023), with ongoing trials further exploring its potential therapeutic effects. Preclinical and clinical studies show that CBD reduces anxiety through partial agonism at 5-hydroxytryptamine (serotonin) 1A (5-HT□A) receptors, engagement of adenosinergic signalling, and desensitisation of transient receptor potential vallinoid 1 (TRPV1) channels (Bergamaschi et al., 2011; Sartim et al., 2016). Magnetic resonance spectroscopy (MRS) in autistic adults has further revealed acute shifts in cortical glutamate and gamma-aminobutyric acid (GABA) after a single CBD dose, suggesting that re-balancing excitatory-inhibitory neurotransmission may also attenuate hyperactivity and related behaviours (Pretzsch et al., 2019). These findings indicate that serotonergic, adenosinergic, and GABAergic systems, alongside the ECS, likely underlie the improvements in hyperactivity, sleep, and anxiety observed with CBD treatment in autism.

The ECS may eventually serve as a pharmacological target for social functioning challenges (Karhson et al., 2016). The precise mechanisms by which CBD affects the ECS and its therapeutic potential remain unclear (Gunasekera et al., 2020). Evidence suggests CBD interacts with ECS components such as CB1 and CB2 receptors, albeit differently to delta-9-tetrahydrocannabinol (THC) (Laprairie et al., 2015). Preclinical studies have reported that CBD directly inhibits of fatty acid amide hydrolase (FAAH) (Bisogno et al., 2001), while human data indicate CBD binds fatty-acid binding proteins (FABPs) that transport anandamide (AEA) to FAAH, limiting AEA hydrolysis (Elmes et al., 2015). This

may increase endocannabinoid tone and modulate signalling at certain G protein-coupled receptors (GPCRs) (Karhson et al., 2016; Wei et al., 2016). Additionally, CBD activates 5-HT_1A receptors, which may underlie its anxiolytic properties, and modulates TRPV1 receptors involved in pain perception and inflammation (Lattanzi et al., 2018). CBD has also been shown to modulate GABA and glutamate neurotransmission, impacting cortical excitation/inhibition (E/I) balance (Pretzsch, Freyberg, et al., 2019a), which is implicated in social processing difficulties in autism (Canitano & Pallagrosi, 2017; Cochran et al., 2015; Ford & Crewther, 2014; Gaetz et al., 2014; Gao & Penzes, 2015; Greenwood et al., 2018; Harada et al., 2011; Marsman et al., 2017; Pinkham et al., 2008; Tebartz van Elst et al., 2014b). While GABA modulation shows promise for addressing core social difficulties in autism (Veenstra-VanderWeele et al., 2017), there are currently no approved pharmacological therapeutics that target this symptom domain, with strong reliance on behavioural interventions. The influence of CBD on E/I mechanisms supports the hypothesis that social processing might be effectively modulated by CBD intervention (Pretzsch, Freyberg, et al., 2019b).

Emerging research suggests potential benefits of CBD in addressing autism-related difficulties (Aran et al., 2021; Efron et al., 2021; Silva Junior et al., 2024). Aran et al. (2021) conducted a placebo-controlled, double-blind, crossover study involving 150 autistic children and young adults, finding significant reductions in disruptive behaviours and improvements in social communication with CBD whole-plant extract (CBD:THC ratio of 20:1) administered three times daily for 12 weeks and titrated from 1 to ~7.5-10 mg/kg/day. Efron et al. (2021) conducted a small pilot study in autistic children with intellectual disability to assess the feasibility and tolerability of 98% CBD oil treatment, administered twice daily for 8 weeks, with a nine-day titration to a target dose of 20 mg/kg/day (500 mg per dose). While promising trends were noted, the study was not powered to detect efficacy. Additionally,

Silva Junior et al. (2024) recently observed significant improvements in social interaction, anxiety, psychomotor agitation, meal frequency, and concentration in autistic children following a low-dose preparation of CBD (CBD:THC ratio of 9:1) for 12 weeks, gradually increased under clinician guidance from ~6 to 70 drops/day. A 12-week randomised, placebo-controlled trial of transdermal cannabidiol gel (ZYN002; 250 or 500 mg/day) in children and adolescents with Fragile X syndrome, who often show autism-like social difficulties, reported a significant reduction in social-avoidance scores in participants with >90% FMR1-gene methylation (Berry-Kravis et al., 2022).

There is variability in CBD study findings for autism and an absence of standardised approaches across randomised controlled trials (RCTs) in this field. Among these trials, there is a mix of open-label assessments, and placebo-controlled parallel and crossover designs, with sample sizes ranging from 8 to 150 participants (Aran et al., 2021; Efron et al., 2021; Heussler et al., 2022). Three trials specifically included predominantly children (Aran et al., 2021; Efron et al., 2021; Silva Junior et al., 2024), while others include autistic adults (Pretzsch et al., 2021; Pretzsch, Freyberg, et al., 2019c; Pretzsch, Voinescu, et al., 2019, 2019). Dosage regimens and administration methods/routes vary across trials, as do primary and secondary outcome measures (Heussler et al., 2022; Silva Junior et al., 2024). Although the 12 ongoing RCTs examining the long-term effects of CBD in neurodevelopmental disorders vary in trial duration (from 6 to 34 weeks), they are increasingly adopting similar methodologies, facilitating comparison (Parrella et al., 2023). These studies highlight the need for further research to confirm CBD's efficacy and safety in addressing core symptoms of autism.

Anxiety, sleep disruption, and parental stress are commonly reported concerns in families of autistic children (Hayes & Watson, 2013; Richdale & Schreck, 2009; Van Steensel et al., 2011). Prior studies have identified potential associations between CBD

administration and reduced anxiety, improved sleep, and decreased caregiver burden, possibly through modulation of the endocannabinoid and serotonergic systems (Bergamaschi et al., 2011; Silva Junior et al., 2024). The inclusion of these outcomes in the current trial reflects growing interest in addressing both core and associated features of autism in clinical research.

The prevalence of autism is increasing world-wide (Talantseva et al., 2023), and prescribing of CBD for autism-related difficulties is also rising (Cairns et al., 2023), although existing clinical trials show variable rigour regarding safety and efficacy (Parrella et al., 2023). We conducted a Phase II randomised, double-blind, placebo-controlled crossover clinical trial to investigate the extent to which oral CBD oil improves social relating in autistic children, as well as other autism-related outcomes (including sleep, anxiety, repetitive behaviours). Safety, tolerability, and acceptability data were also collected. Our primary hypothesis was that 12-week administration of CBD oil would positively impact social outcomes for autistic children, as measured by the Social Responsiveness Scale – 2nd Edition (SRS-2). Specifically, we hypothesised that participants would exhibit a significant reduction in SRS-2 scores from baseline to 12 weeks. Secondary aims of the study included evaluating the effects of CBD on anxiety levels in autistic children, as well as parental stress, with the expectation that both would decrease following 12-week CBD oil administration.

<div align="center">**Methods**</div>

Ethics, Consent, and Registration

This trial was prospectively registered under the Australian New Zealand Clinical Trials Registry (ACTRN12622000437763) and received ethics approval from the Deakin University Human Research Ethics Committee (DUHREC 2020-071) prior to enrolment of the first participant. Written informed consent was obtained from the parents/guardians of all participants prior to participation in the study, and assent was obtained from participants when appropriate. The only deviation from the protocol was that adherence to the daily Treatment Log was lower than anticipated for some participants.

Trial Design

This randomised, double-blind, placebo-controlled crossover trial was conducted at Deakin University's School of Psychology in Melbourne, Australia. For each participant, the trial spanned a total of 32 weeks, divided into two 12-week intervention periods, with an 8-week washout period in between. Eligible participants were children (5-12 years old) with an autism spectrum disorder (ASD) diagnosis per DSM-5 criteria. Evidence of diagnosis was obtained from the participant's clinician. The trial aimed to investigate the effects of weight-based dosing of a medicinal cannabis oil product (Cannabidiol: Medigrowth CBD100) on social relating in autistic children. There were no changes made to eligibility criteria once the trial had commenced. No scientific or methodological amendments were made after enrolment began. One administrative amendment (ethics approval 14 Aug 2023) authorised the use of Calendly to schedule visits during Period 2 of the trial. This had no impact on eligibility criteria, interventions, outcomes, or the statistical plan.

Participants

Thirty-four children were enrolled in the study. Five participants withdrew their participation during the first intervention period, leaving a total of 29 participants completing the trial. Formal IQ testing was not part of the study protocol; therefore, IQ data are not reported.

Inclusion and exclusion criteria for study participation is in Table 1, participant demographics in Table 2, and participant medications in Table 3.

Table 1

Inclusion and exclusion criteria

Inclusion criteria	1. Aged 5 to 12 years inclusive.
	2. Diagnosis of Autism Spectrum Disorder (ASD) confirmed by ADOS-2 or equivalent assessment.
	3. Stable interventions for at least 4 weeks prior to randomisation.
	4. Availability of a parent or guardian to provide consent and complete assessments.
	5. Normal or corrected-to-normal hearing and vision.
Exclusion criteria	1. Use of any cannabinoid product (including CBD or THC preparations) within the past 30 days, or ongoing, chronic use of such products.
	2. Diagnosis of known genetic disorders or primary psychiatric disorders other than ASD.
	3. Medical conditions impacting participation or confounding study results.
	4. Changes in therapies or medications within 4 weeks prior to randomisation.
	5. Contraindications to the study intervention or current use of specific medications.

Table 2.

Demographics of participants and their families (N = 29)

Characteristic	N (%)
Age (years)	5-12 (M = 9.62, SD = 2.05)
SRS-2 Total Score (baseline)	93.7 (29.6)
Vineland Adaptive Behaviour Composite (baseline)	68.5 (15.1)
Participant Gender	
Male	18 (62.1%)
Female	11 (37.9%)
Number of Children in the Family	
1	7 (24.1%)
2	9 (31.0%)
3	6 (20.7%)
4	3 (10.3%)
More than 4	2 (6.9%)
Prefer not to say	2 (6.9%)
Parent/Guardian Ethnicity	
Caucasian	37 (63.8%)
Middle-Eastern	2 (3.4%)
Asian	9 (15.5%)
African	1 (1.7%)
Prefer not to say	2 (3.4%)
Other	2 (3.4%)

Languages Spoken at Home

English	22 (75.9%)
English and another language	7 (24.1%)

Ethnicity of Participants

Caucasian	20 (69.0%)
Middle-Eastern	2 (6.9%)
Asian	3 (10.3%)
African	1 (3.4%)
Prefer not to say	2 (6.9%)

Parent/Guardian Education Level

Some High School	1 (1.7%)
High School	10 (17.2%)
Diploma	9 (15.5%)
Undergraduate Certificate	2 (3.4%)
Bachelor's Degree	18 (31.0%)
Master's Degree	10 (17.2%)
Ph.D. or higher	3 (5.2%)
Prefer not to say	2 (3.4%)
Other	3 (5.2%)

Annual Household Income

$25,000 - $50,000	4 (13.8%)
$50,000 - $100,000	2 (6.9%)
$100,000 - $200,000	15 (51.7%)
More than $200,000	2 (6.9%)

| Prefer not to say | 6 (20.7%) |

No baseline differences were detected between the two treatment sequence groups. Age, sex, and every prespecified baseline outcome showed non-significant sequence comparisons (all $p > .05$; see Supplementary Table S1).

Table 3

Existing participant medications maintained throughout trial

Medication	N
Melatonin	9
Non-stimulant ADHD Medications (Intuniv, Clonidine)	2
Atypical antipsychotics (Risperidone, Aripiprazole, Olanzapine, Quetiapine, Ziprasidone)	12
Methylphenidate (Ritalin, Ritalin SR, Concerta, Metadate ER, QuilliChew ER, Cotempla XR-ODT)	10
SSRIs (Fluoxetine, Fluvoxamine maleate, Sertraline)	10
SNRIs (Strattera)	2

Intervention

Medigrowth CBD100 oil was distributed in a 30 mL bottle, with each millilitre of oil containing 100 mg of cannabidiol (CBD) and a negligible amount of Delta-9-trans-Tetrahydrocannabinol (THC) not exceeding 1 mg/mL. CBD100 is formulated with medium-chain triglyceride (MCT) excipients and naturally occurring terpenes including Nerolidol, Alpha-Bisabolol, d-Limonene, β-Caryophyllene, and Alpha-Humulene. The total cannabinoid content per bottle was 3000 mg. In addition, the placebo for the CBD100 medication consisted of MCT as an excipient, matched to CBD100 in taste to maintain blinding integrity throughout the trial. Taste and smell similarity between the CBD and placebo oils was established during product development and confirmed through informal testing with independent staff not involved in the trial. Although no formal blinding assessment was conducted, procedures were designed to minimise the potential for unblinding by participants and caregivers.

Participants were randomised 1:1 to the two sequences (CBD-Placebo vs Placebo-CBD) using a computer-generated block randomisation scheme with a block size of 4. Given the 8-week washout and balanced allocation, carryover was considered unlikely a priori. Therefore, no formal period-by-sequence test was performed. Baseline equivalence by sequence is shown in Supplementary Table S1. The allocation sequence was generated by a senior researcher on the team and stored in a secure electronic file accessible only to the designated team member responsible for assignment. Both the active CBD oil and the placebo were prepared to be identical in appearance, taste, and packaging, ensuring that participants, caregivers, and outcome assessors remained blinded throughout the trial.

Medigrowth CBD100 was administered orally in weight-based doses calculated by the investigator. Parents/guardians received in-person training at T0 on dose administration (syringe demonstration, timing, and recording procedures). Full step-by-step instructions are provided in Supplementary Methods S1 (Parent Administration Instructions). In each intervention period, the starting dose was 5 mg/kg body weight/day. The dose was increased to 10 mg/kg/day by the second week, with parents or guardians trained to facilitate sublingual administration during the first visit. We adopted this schedule as it sits within the paediatric safety range established in epilepsy trials (Devinsky et al., 2018; Thiele et al., 2018), reaches plasma levels sufficient for FAAH and $5\text{-HT}_1\text{A}$ modulation, associated with anxiolysis (Bisogno et al., 2001; Campos & Guimarães, 2008), and aligns with the doses used in similar CBD in autism RCTs (Aran et al., 2021; Efron et al., 2021), allowing cross-study comparison. Placebo oil was administered following the same protocol. Intervention adherence was monitored through a daily Treatment Log. Interventions were given as an add-on to any ongoing stable medication (no change in four weeks prior to study entry).

Measures

Primary Outcome

The primary outcome was the *Social Responsiveness Scale – Second Edition* (SRS-2; Constantino & Gruber, 2012), a 65-item parent-report questionnaire used to assess the severity of autism spectrum symptoms in naturalistic social contexts. It comprises five subscales:

- ⬚ Social Awareness: the ability to pick up on social cues;

- ⬚ Social Cognition: the ability to interpret social signals;

- ⬚ Social Communication: expressive and receptive communication skills in social contexts;

- ⬚ Social Motivation: the level of interest in engaging with others socially;

- ⬚ Restricted Interests and Repetitive Behavior (RRBs): the presence and severity of repetitive or stereotyped behaviours. Total and subscale scores were used in analyses.

The primary outcome was the Social Responsiveness Scale-Second Edition (SRS-2) Total T-score. In addition to the SRS-2 Total T-score (primary outcome), we also examined the Social Communication Index (SCI) and individual subscales to explore whether specific domains of social functioning were differentially affected by CBD. The SCI is a composite domain score derived from the Awareness, Cognition, Communication, and Motivation subscales, and is reported alongside the individual subscales to provide a more detailed understanding of potential treatment effects.

Secondary Outcomes

- ⬚ Repetitive Behavior Scale – Revised (RBS-R; Bodfish et al., 2000): A caregiver-report measure assessing the breadth and severity of repetitive behaviours in children with autism.

- Vineland Adaptive Behavior Scales – Third Edition (VABS-3; Sparrow et al., 2016): A semi-structured caregiver interview that assesses adaptive functioning in Communication, Daily Living Skills, and Socialization domains.

- Pediatric Quality of Life Inventory (PedsQL; Varni, 1998): A parent-report measure assessing children's health-related quality of life across physical, emotional, social, and school functioning.

- Behavior Rating Inventory of Executive Function – Second Edition (BRIEF-2; Gioia et al., 2015): Evaluates executive functioning in everyday settings, as reported by caregivers.

- Personal Wellbeing Index – School Children (PWI-3; Cummins & Lau, 2005): A self-report measure evaluating children's subjective wellbeing across multiple life domains.

- Developmental Behaviour Checklist – Second Edition (DBC-2; Einfeld & Tonge, 1992, 2002): A parent-report tool assessing behavioural and emotional disturbance in children with developmental disabilities, including specific subscales for social relating and anxiety.

- Autism Parenting Stress Index (APSI; Silva & Schalock, 2012): A parent-report questionnaire that measures stress levels specifically related to parenting a child with autism.

- PROMIS Early Childhood Parent-Report – Anxiety (PROMIS Health Organization and Assessment Center, 2014): Evaluates parental observations of a child's anxiety symptoms.

- PROMIS Early Childhood Parent-Report – Sleep Health (PROMIS Health Organization and Assessment Center, 2014): Assesses sleep-related behaviours and difficulties in young children.

- PROMIS Early Childhood Parent-Report – Social Relationships (PROMIS Health Organization and Assessment Center, 2014): Captures the quality of the child's social interactions and connectedness, as observed by parents.

To limit multiplicity and align outcomes with our domains of interest, we selected nine outcomes for secondary analysis: PROMIS–Social Relationships, DBC-2 Social Relating, PROMIS–Anxiety, DBC-2 Anxiety, VABS-3 Adaptive Behavior Composite, VABS-3 Communication, VABS-3 Daily Living Skills, VABS-3 Socialization, and APSI. All other collected subscales from these instruments are treated as exploratory and are summarised descriptively in the Supplementary Table S2.

Sample Size

A power analysis was conducted using the software package, G*Power (Faul & Erdfelder, 1992). The alpha level used for this analysis was $p < .05$. A sample size of 34 was determined for the detection of a moderate-large effect size ($f^2 = .25$, power = .8). The determined sample size is consistent with a study involving acute administration of CBD in autistic individuals (Pretzsch, Freyberg, et al., 2019c), reflecting our best estimate given the limited available trials for comparison.

Recruitment

Recruitment took place between January and March 2023. During the first intervention period of the trial, an attrition rate of 14.7% reduced the sample from 34 to 29. One participant was lost to follow-up, and four withdrew their participation, discontinuing intervention. Reasons for withdrawal included family-related difficulties for three participants (two families) and gastrointestinal discomfort for one other. Three of the four

participants who discontinued their involvement were allocated the active intervention in the first intervention period.

Procedure

Participants underwent an initial telephone screening to confirm eligibility and were then enrolled in the trial, comprising two intervention periods separated by an 8-week washout period, see Figure 1. Each period involved administration of either Medigrowth CBD100 or placebo oil, with the order of intervention randomised. Four testing visits took place throughout the trial. The first visit, T0, served as the baseline assessment for intervention period one, followed by T1 at 12 weeks. T2 marked the baseline assessment for intervention period two, with T3 occurring at 12 weeks thereafter, concluding the study's assessment timeline.

Figure 1. Study design illustrating two 12-week administration periods separated by an 8-week washout. Each period includes baseline and follow-up assessments with EEG recordings (brain icon) and behavioural (parental) questionnaires (paper icon).

Given the lack of pharmacokinetic data for CBD in children, an 8-week interval ensured adequate washout time for CBD100, which is at least four weeks (Thiele et al., 2018). The placebo condition served as the within-participants control measure to investigate CBD-specific outcomes in behaviour.

During the testing visits, parents or guardians of participants were required to complete behavioural questionnaires (Table 4). The SRS-2 and BRIEF 2 were administered in paper format, while all other measures were completed electronically via REDCap. The

VABS-3 and the DBC-2 were completed through their respective psychological assessment publisher platforms. Additionally, a post-study survey, administered via REDCap, collected economic information from the parents or guardians. The trial also involved a cohort of participants undergoing electroencephalography (EEG) recording to capture aperiodic neural activity. We conducted 5 minutes of eyes-open resting state EEG (64-channel), which will be reported separately.

Parents or guardians of participants provided ASD diagnostic reports, completed behavioural questionnaires, and administered the study intervention daily. They also filled out a daily Treatment Log and assisted their children during testing visits. The online Treatment Log captured detailed information on administration, adherence, and child wellbeing. At T0 the researcher demonstrated administration of the calculated daily dose and advised splitting the total into two administrations (morning and evening) at consistent times. Parents recorded each dose in the daily Treatment Log (see Supplementary Methods S1). Specifically, the log recorded whether the oil was taken (and how much), the time(s) of administration, whether it was consumed with food (and what food), and any administration-related issues. It also included items assessing the child's appetite and behavioural presentation, including a simplified emotion regulation tool using a "Feelings Thermometer" framework. Parents indicated which emotional "zones" their child experienced that day (e.g., Green = calm, Yellow = excited, Blue = withdrawn, Red = angry). Open-ended prompts allowed for reporting of any adverse events, concerns, or notable behavioural observations. A copy of the Treatment Log is included in the Supplementary Form S1.

Statistical Analysis

Data analysis was conducted using mixed models within the Jamovi statistical software package (version 2.5.3). Mixed models were chosen due to their ability to account for within-subject correlation in crossover designs while accommodating fixed and random effects. For the primary analysis, a mixed-effects model was fitted to the outcome variable, with Time (Baseline, 12 Weeks) and Intervention as fixed effects. Participant was included as a random effect to account for within-subject correlation. The following parameters are reported: β (unstandardised coefficient), which represents the estimated treatment effect, i.e. the difference in mean change from baseline between the CBD and placebo periods; SE (standard error of β); $F(df)$, the omnibus F-statistic for the treatment effect with its numerator and denominator degrees of freedom in parentheses; and ηp^2 (partial eta-squared), which expresses effect size as the proportion of outcome variance uniquely attributable to the Intervention factor after controlling for other terms in the model.

For secondary outcomes, multiplicity was controlled using a Bonferroni adjustment within prespecified outcome domains (Anxiety; Social Functioning; Caregiver Stress; Adaptive Functioning/VABS-3). Adjusted p-values, $p_{(adj)}$, are reported for secondary outcomes unless otherwise specified ($\alpha = .05$). The estimated intervention effect along with 95% confidence intervals and associated p-values were reported. The assumption of normality was assessed visually through histograms and Q-Q plots and confirmed by the Shapiro-Wilk test. All analyses were conducted blind to the intervention condition, ensuring objectivity and minimising potential bias in the interpretation of results. No missing data occurred for any outcome. Therefore, no imputation and no analysis of missingness were required. Had missing data arisen, the mixed-effects framework would have accommodated observations missing at random. Given the small sample size, sensitivity analyses were not

conducted, and this is acknowledged as a limitation. To account for within-subject variability in the crossover design, mixed-effects models were employed to test for a Time × Condition interaction. This approach avoided the use of pre–post difference scores, which have reduced sensitivity to condition effects.

The CONSORT flow diagram (Figure 2) illustrates participant enrolment, allocation to intervention groups, follow-up, and analysis, including reasons for exclusions and dropouts. See Supplementary Table S3 for CONSORT Checklist.

Figure 2. CONSORT flow diagram depicting enrolment, allocation, follow-up and analysis

Data completeness

Data completeness was 100% across measures. All participants who completed the trial provided both baseline and 12-week assessments, with no missing visits or item-level omissions.

Primary Outcome

SRS-2: The Time by Intervention interaction indicated a greater reduction (i.e., improvement) in SRS-2 Total scores for CBD (mean difference = -17.0 points) compared to placebo (mean difference = -7.0 points); however, this interaction was not statistically significant (β = -11.15, SE = 7.19, p = .125).

For the Social Communication Index, the reduction in scores for CBD (mean difference = -13.8 points) compared to placebo (mean difference = -4.6 points) was not statistically significant (β = -9.92, SE = 5.81, p = 0.092), (see Figure 3). Change-from-baseline plots of the SRS-2 Total and SCI are provided in Supplementary Figure S1. Greater reduction in scores following CBD compared to placebo were also observed for the SRS-2 subscales Awareness (CBD: -2.6 points, Placebo: -0.9 points; β = -1.77, SE = 1.030, p = .090) and Motivation (CBD: -3.3 points, Placebo: -0.8 points; β = -2.48, SE = 1.265, p = .053), although did not reach statistical significance. For Cognition (CBD: -2.8 points, Placebo: -1.3 points; β = -1.787, SE = 1.565, p = .257), Communication (CBD: -5.1 points, Placebo: -1.7 points; β = -3.84, SE = 2.71, p = .161) and Restricted Repetitive Behaviours (CBD: -2.9 points, Placebo: -2.1 points; β = -1.23, SE = 1.644, p = .458) there were no intervention effects.

Figure 3. Time by Intervention effects of CBD (orange) and placebo (green) on (A) Social Responsiveness Scale (SRS-2) Total scores and (B) Social Communication Index composite scores from baseline to 12 weeks. Points are group means with standard-error (SE) bars. Lower scores indicate fewer social-communication difficulties. Sample sizes at each time point: CBD n = 29 / 29, placebo n = 29 / 29.

Secondary Outcomes

Analyses focus on the nine a priori secondary endpoints defined in Methods.

Social Functioning: Three secondary measures probed social relating: PROMIS-Social, Vineland Socialization, and DBC-2 Social Relating. For the PROMIS-Social, an interaction effect was observed that did not remain after Bonferroni correction (CBD: +1.7 points, Placebo: -0.2 points; $\beta = 1.992$, SE = 0.935, $p = .036$; $p_{(adj)} = .072$) with greater improvement following CBD intervention compared to placebo. There was no significant interaction effect observed for the VABS-3 subscales Communication (CBD: +2.4 points, Placebo: +1.3 points; $\beta = 1.82$, SE = 2.40, $p = .451$; $p_{(adj)} = 1.000$) or Socialization (CBD: +4.4 points, Placebo: +2.4 points; $\beta = 2.71$, SE = 3.25, $p = .406$; $p_{(adj)} = 1.000$) . Lastly, the DBC-2 Social Relating subscale showed a significant interaction effect (CBD: -2.55 points, Placebo: -0.29 points; $\beta = -2.352$, SE = 0.918, $p = .012$; $p_{(adj)} = .024$) suggesting a moderate impact of CBD intervention on social relating symptoms.

Anxiety: The PROMIS-Anxiety and the DBC-2 Anxiety subscales were used to measure changes in anxiety following CBD compared to placebo. For the PROMIS-Anxiety subscale, there appeared to be a reduction in anxiety for CBD (mean difference = -4.1 points) compared to placebo (mean difference = -0.8 points); but the difference did not reach statistical significance (β = -3.119, SE = 1.660, p = .064; $p_{(adj)}$ = .128). Conversely, a significant interaction effect for the Anxiety subscale from the DBC-2 was observed, indicating reduced anxiety symptoms following CBD (CBD: -3.14 points, Placebo: +0.2 points; β = -3.20, SE = 0.944, p = .001; $p_{(adj)}$ = .002).

Adaptive Behaviour: There was no significant effect of CBD on VABS-3 Adaptive Behaviour Composite (ABC) score compared to placebo (CBD: +2.4 points, Placebo: +1.0 points; β = 2.06, SE = 2.67, p = .443; $p_{(adj)}$ = 1.000). Similarly, there were no effects of CBD on VABS-3 subscale Living Skills (CBD: +1.0 points, Placebo: +0.1 points; β = 1.91, SE = 2.78, p = 0.493; $p_{(adj)}$ = 1.000).

Parental Stress: There was a significant improvement in parental stress following the CBD intervention compared to placebo as measured by the APSI (CBD: -5.7 points, Placebo: -1.4 points; β = -4.6271, SE 2.26, p = .044, $p_{(adj)}$ = .044). Change-from-baseline plots are shown in Supplementary Figure S2.

Figure 4. Time by Intervention effects of CBD (orange) and placebo (green) on (A) The

Vineland Adaptive Behaviour Composite Score, (B) Vineland Socialization (subscale), (C)

DBC-2 Social Relating (subscale), (D) PROMIS Social, (E) DBC-2 Anxiety, (F) PROMIS

Anxiety and (G) Autism Parental Stress Index. Points are group means with standard-error

(SE) bars. Lower scores indicate fewer social-communication difficulties. Sample sizes at

each time point: CBD n = 29 / 29, placebo n = 29 / 29.

Intervention effects on the discussed outcome measures from baseline to 12-weeks are presented in Table 4 and Table 5. Exploratory analyses of the remaining secondary outcome measures are presented in the Supplementary Table S2.

Adverse Events

Parents completed a daily treatment log that specifically probed for adverse events and general health/wellbeing, ensuring regular assessment of potential side effects throughout the trial. During the trial, there were two adverse events recorded. One participant experienced abdominal discomfort on day 4 of CBD intervention, as reported by their parent, leading to the discontinuation of intervention after 7-days and withdrawal from the trial. This participant had pre-existing gastrointestinal issues, which may have contributed to the reported discomfort. Another participant also reported gastrointestinal discomfort during the CBD condition, but this subsided after one week and the participant remained in the trial. Medical consultations were provided to the parents by a licensed medical practitioner, offering guidance on managing symptoms and assessing the suitability of continued participation in the study. No other adverse events were reported throughout the trial duration, indicating a generally well-tolerated intervention.

Table 4.

Summary of intervention effects on primary outcome measure (SRS-2 – Total Score), and

composite and subscale scores from baseline to 12-weeks.

Measure	Intervention	Time Point	Mean (SD)	*F*(*df*)	β	SE	ηp²	*p*-value
SRS-2 - Total Score	Placebo	Baseline	121.0 (35.8)	2.47 (1,80)	-11.15	7.19	0.031	.125
		12 weeks	114.0 (34.2)					
	CBD	Baseline	117.0 (37.3)					
		12 weeks	100.0 (34.5)					
SRS-2 - Social Communication	Placebo	Baseline	95.0 (30.2)	2.93 (1,80)	-9.92	5.81	0.036	.092
		12 weeks	90.4 (29.6)					
	CBD	Baseline	92.7 (30.9)					
		12 weeks	78.9 (27.9)					
SRS-2 - Awareness	Placebo	Baseline	15.2 (4.94)	2.99 (1,80)	-1.77	1.03	0.036	.090
		12 weeks	14.3 (4.76)					
	CBD	Baseline	15.0 (4.76)					
		12 weeks	12.4 (4.03)					
SRS-2 - Motivation	Placebo	Baseline	17.7 (7.05)	3.89 (1,80)	-2.48	1.27	0.046	.053
		12 weeks	16.9 (7.25)					
	CBD	Baseline	17.8 (6.04)					

		12 weeks	14.5 (6.65)					
SRS-2 - Cognition	Placebo	Baseline	22.6 (7.55)	1.17 (1,80)	-1.79	1.57	0.032	.257
		12 weeks	21.3 (7.15)					
	CBD	Baseline	22.4 (7.68)					
		12 weeks	19.6 (5.95)					
SRS-2 – Communication	Placebo	Baseline	39.6 (13.0)	2.08 (1,80)	-3.84	2.71	0.025	.161
		12 weeks	37.9 (12.3)					
	CBD	Baseline	37.5 (14.0)					
		12 weeks	32.4 (13.2)					
SRS-2 - Restricted Repetitive Behaviours	Placebo	Baseline	25.6 (7.14)	0.71 (1,79)	-1.23	1.64	0.008	.458
		12 weeks	23.5 (6.33)					
	CBD	Baseline	24.3 (7.98)					
		12 weeks	21.4 (7.92)					

Notes: SRS-2=Social Responsiveness Scale, Second Edition.

Table 5.

Summary of intervention effects on secondary outcome measures from baseline to 12-weeks.

Measure	Intervent-ion	Time Point	Mean (SD)	$F(df)$	β	SE	ηp^2	*p*-value	*p_adj* (Bonferroni)
PROMIS Anxiety	Placebo	Baseline	20.4 (7.55)	3.53 (1,79)	-3.12	1.66	0.043	.064	.128
		12 weeks	19.6 (6.50)						
	CBD	Baseline	21.8 (7.34)						
		12 weeks	17.7 (4.69)						
DBC-2 - Anxiety	Placebo	Baseline	10.7 (4.47)	11.48 (1,78)	-3.20	0.94	0.127	.001	**.002***
		12 weeks	10.9 (4.31)						
	CBD	Baseline	11.4 (4.45)						
		12 weeks	8.26 (2.82)						
PROMIS Social	Placebo	Baseline	19.9 (5.28)	4.54 (1,78)	1.99	0.94	0.055	.036	.072
		12 weeks	19.7 (4.98)						
	CBD	Baseline	19.8 (4.90)						
		12 weeks	21.5 (4.90)						

Measure	Group	Time	Mean (SD)						
DBC-2 – Social Relating	Placebo	Baseline	8.48 (4.59)	6.57 (1,78)	-2.35	0.92	0.077	.012	**.024***
		12 weeks	8.19 (3.95)						
	CBD	Baseline	9.18 (3.96)						
		12 weeks	6.63 (3.33)						
Autism Parental Stress Index	Placebo	Baseline	23.9 (11.7)	4.19 (1,78)	-4.63	2.26	0.051	.044	**.044***
		12 weeks	22.5 (9.58)						
	CBD	Baseline	25.8 (12.5)						
		12 weeks	20.1 (10.4)						
VABS-3 ABC	Placebo	Baseline	67.4 (15.8)	0.60 (1,78)	2.06	2.67	0.007	.443	1.000
		12 weeks	68.4 (17.2)						
	CBD	Baseline	68.6 (14.4)						
		12 weeks	71.0 (16.8)						
VABS-3 Communication	Placebo	Baseline	67.0 (20.2)	0.57 (1,78)	1.82	2.40	0.007	.451	1.000
		12 weeks	68.3 (20.3)						
	CBD	Baseline	68.6 (18.7)						

Measure	Group	Time	Mean (SD)	β (SE)	F(df)				
		12 weeks	71.0 (20.4)						
VABS-3 Living Skills	Placebo	Baseline	69.2 (17.5)	0.47 (1,78)	1.91	2.78	0.006	.493	1.000
		12 weeks	69.3 (18.1)						
	CBD	Baseline	69.8 (17.5)						
		12 weeks	70.8 (17.5)						
VABS-3 Socialization	Placebo	Baseline	64.4 (16.9)	0.70 (1,78)	2.71	3.25	0.008	.406	1.000
		12 weeks	66.8 (19.4)						
	CBD	Baseline	66.9 (15.8)						
		12 weeks	71.3 (19.2)						

Notes. DBC-2=Developmental Behaviour Checklist, Second Edition, PROMIS=Patient-Reported Outcomes Measurement Information System, VABS-3=Vineland Adaptive Behavior Scales, Third Edition, ABC=Adaptive Behavior Composite. $F(df)$ = omnibus F statistic (numerator, denominator df) from the linear mixed model; β = unstandardised coefficient representing the estimated treatment effect (CBD – placebo) expressed as the difference-in-change from baseline; SE = standard error of β; ηp^2 = partial eta-squared effect size. Negative values indicate improvement for scores where lower = better (e.g., SRS-2, RBS-R, APSI); positive values indicate improvement where higher = better (e.g., VABS-3 scales). * $p < .05$.

Discussion

This randomised, double-blind, placebo-controlled, crossover trial is among the first to investigate the effects of oral CBD oil on social relating in autistic children, with mental health and parental stress as secondary outcomes. The trial addresses a critical gap by evaluating chronic CBD administration in autistic children, an area with few RCTs systematically assessing long-term effects despite the increasing off-label prescribing of CBD in this population. Improvements were observed in secondary measures of social relating and anxiety symptoms as well as a reduction in parental stress. These preliminary findings contribute to the growing body of research investigating the potential therapeutic effects of CBD in autistic children. The premise of this research stemmed from the growing recognition of the involvement of the ECS in social relating, specifically in autism, suggesting a potential role for CBD in modulating social functioning for autistic children (Wei et al., 2015; Zamberletti et al., 2017). CBD has been shown to bind to FABPs that transport AEA to FAAH, limiting AEA hydrolysis (Elmes et al., 2015) and, at similar concentrations, to modulate 5-HT☐A, $GABA_A$ and TRPV1 receptors (Bakas et al., 2017; Campos & Guimarães, 2008; Iseger & Bossong, 2015). These mechanisms may influence circuits relevant to social-reward processing and reduce amygdala-driven anxiety (Wei et al., 2016; Zamberletti et al., 2017). Medigrowth CBD100 (<1 mg/mL THC) therefore relies on CBD-related mechanisms rather than CB_1 agonism, which may explain the moderate, yet clinically meaningful gains observed, in contrast to the larger effects reported with higher-THC whole-plant extracts (Aran et al., 2021).

The present trial's findings contribute preliminary evidence of the effect of CBD on social relating and anxiety symptoms in autistic children, aligning with previous studies indicating the potential for CBD to ameliorate core symptoms of autism (Aran et al., 2021; Silva Junior et al., 2024). Existing RCTs have administered distinct cannabinoid

formulations, including a 20:1 CBD:THC whole-plant extract (Aran et al., 2021), a 98% purified CBD isolate (Efron et al., 2021), and a 9:1 CBD:THC extract (Silva Junior et al., 2024). The present trial investigates Medigrowth CBD100, a CBD-dominant oil that retains terpenes, with effects expected to arise from FAAH inhibition, partial 5-HT$_1$A agonism, and positive allosteric modulation of GABA$_A$ receptors (Bakas et al., 2017; Bisogno et al., 2001; Campos & Guimarães, 2008). A recent multicentre phase-II RCT of purified CBD oral solution (10 mg/kg/day) found no improvement on Vineland-3 Socialization or other behavioural endpoints in 103 autistic children and adolescents (GW Research Ltd, 2024). The difference in outcomes between that study and ours may suggest an entourage effect, in which the terpenes present in Medigrowth CBD100 act synergistically with CBD to support social and anxiolytic outcomes (Russo, 2011).

While the effect of CBD oil on the primary outcome measure, the SRS-2, did not reach statistical significance, changes in the SRS-2 Total scores and the Social Communication Index suggest a potential benefit of CBD intervention, albeit with small effect sizes. SRS-2 Total scores decreased, on average, by 17 points following CBD oil, compared with a 7-point reduction after placebo oil. The SRS-2 manual indicates that a 10-point raw-score change shifts a child down one severity band (e.g., from moderate to mild). Therefore, the 17-point decrease represents a clinically meaningful improvement in social functioning. The study employed both total and subscale scores from the SRS-2 as outcome measures to capture global social responsiveness as well as domain-specific effects, thereby providing a comprehensive evaluation of CBD's impact on social functioning. Given that 11 participants had intellectual disability, it is important to note that certain assessment measures may have been better suited for their evaluation than others. For instance, individuals who were non-verbal or faced sensory challenges might not have been adequately captured by measures emphasising higher levels of communication abilities such as the SRS-2.

In terms of secondary outcomes, significant effects were observed for social functioning measures, such as the DBC-2 Social Relating subscales, indicating a moderate positive effect of CBD intervention on social relating symptoms. Furthermore, 12-week CBD administration demonstrated a reduction in anxiety symptoms, as evidenced by significant interaction effects for anxiety on the DBC-2 Anxiety subscale. This suggests a potential interplay between social anxiety and social relating, where CBD might reduce social anxiety, thereby improving social interactions, or enhance social relating, which could in turn alleviate anxiety symptoms (Bergamaschi et al., 2011). Alternatively, CBD could simultaneously impact both social relating and anxiety symptom domains (Crippa et al., 2011; Shannon, 2019; Silva Junior et al., 2024). These findings underscore the importance of further research to elucidate the specific mechanisms underlying the effect of CBD on social relating and mental health in autistic individuals, ultimately informing the development of targeted interventions to improve outcomes in this population.

Parents/guardians showed an improvement in parental stress scores following the 12-week CBD intervention in their children. Parenting an autistic child has been associated with greater parenting stress compared with parenting a neurotypical child, and improvements in parental well-being have been linked to enhanced outcomes for autistic children, including reduced behavioural difficulties (Hayes & Watson, 2013). This finding raises questions regarding the attribution of child improvement to CBD, parenting factors, or a combination of both. It is also possible that parents willing to enrol their child in an RCT might differ in certain characteristics, such as being more proactive in seeking interventions or having different stress-coping strategies, compared to those who do not participate. This significant finding suggests there is value in probing both child and parental well-being in autism-related clinical trials. Further research should consider parental well-being to disentangle the potential mechanisms underlying the observed outcomes.

The observed improvements in social relating and anxiety reduction following the CBD intervention underscore the need for further research in this area, particularly considering the limited pharmacological options available for addressing social difficulties and anxiety in autism (Warren et al., 2011). The inclusion of specific terpenes in the CBD formulation, such as Nerolidol, Alpha-Bisabolol, d-Limonene, β-Caryophyllene, and Alpha-Humulene, may have contributed to the therapeutic effects observed. This would be consistent with the proposed synergistic interactions between cannabinoids and terpenes (Russo, 2011). This trial reveals that CBD may represent a promising intervention due to its favourable safety profile, non-intoxicating nature, and lack of intoxicating effects, making it an attractive candidate for further investigation in paediatric populations. Two participants reported experiencing gastrointestinal discomfort as a side effect during the CBD condition, with one child withdrawing from the trial before titrating to 10 mg/kg/day. This prompts speculation on whether the dosage of CBD administered may have been too high for some participants, and if a lower dose could potentially yield similar beneficial outcomes with fewer side effects. Further investigation into dosage optimisation is warranted to address these concerns and enhance tolerability in future trials.

There were several limitations inherent to this trial. Given the two-period crossover design, we examined baseline comparability by sequence (Supplementary Table S1). A formal carryover test was not conducted, and although the 8-week washout and balanced allocation reduce this risk, residual carryover cannot be entirely excluded. The pilot-sized sample and recruitment from a single site may constrain the generalisability of the reported findings. Due to limitations in sample size, stratification was not feasible, although it would have benefitted the heterogeneity observed across participants, particularly regarding cognitive levels and communication abilities. Although all participants had documented clinical diagnoses of ASD confirmed by external clinicians, standardised observational

assessments (e.g., ADOS-2 or CARS) were not included in the study protocol, which may limit diagnostic consistency across the sample. Future research endeavours should aim to conduct larger-scale, multi-site trials. By involving multiple research sites, trials can recruit larger and more diverse participant pools, improve the representativeness of findings and increase statistical power. In larger trials containing clinical heterogeneity among participants, stratification could provide insights into intervention mechanisms by identifying specific characteristics within subgroups. Additionally, the anxiolytic and sleep effects of CBD have been identified as exhibiting an inverted U-shape dose-response curve, highlighting the complexity and critical nature of dosage and administration methods in clinical trials involving this compound (Narayan et al., 2022). Tailoring dosages to individual responsivity could also lead to more precise and effective provision of CBD.

Two parents anecdotally reported differences in oil consistency between the CBD and placebo formulations. This difference may have increased the risk of unblinding, particularly in families with siblings assigned to different conditions. We did not administer a post-study blinding questionnaire; therefore, blinding integrity could not be verified. Thus, future studies should standardise formulations, assess their impact on outcome measures, and include a formal blinding integrity check. Although the Treatment Log offered prompts and an open-text field, we did not administer a validated symptom checklist. Consequently, very mild or transient events may not have been reported, potentially underestimating the true adverse event frequency. Despite limitations concerning statistical power, cohort heterogeneity, oil formulation, diagnostic verification, and adverse event assessment, the efficient recruitment observed in this pilot study suggests the feasibility of conducting larger investigations to explore the potential benefits of CBD in managing challenges associated with autism.

Given the lack of effective pharmacological therapeutics for social relating in autism, without side effects (Nurmi et al., 2013; Sharma & Shaw, 2012), there is a critical need to

develop novel targeted interventions. This RCT undertook a symptom-specific approach to investigating the effects of CBD on social relating in autistic children. The findings contribute to the current understanding regarding novel therapeutics with acceptable safety profiles to support the social difficulties experienced by autistic children. By combining CBD administration with behavioural testing specifically targeting social relating, this study offers a comprehensive exploration of the therapeutic effects of CBD in a population with limited pharmacological therapeutic options.

Conclusion

This trial, while preliminary, represents a significant step towards understanding the therapeutic potential of CBD in autism. With an emphasis on social relating difficulties, this study provides insights into the effects of CBD on one of the core symptoms of autism. Overall, the results suggest that across domain-specific measures there were statistically significant effects alongside positive trends for social relating and anxiety reduction following the CBD intervention compared to placebo. While further research is needed to validate and extend these findings, the results highlight the promise of CBD as a novel intervention for improving social wellbeing, and thus quality of life of autistic individuals and their families. These preliminary findings of improvement in social outcomes following chronic CBD oil administration call for larger, multi-site trials to elucidate the therapeutic efficacy of CBD in treating social challenges associated with autism and provide direction on which outcome measures should be employed. This trial serves as a critical step towards enhancing our understanding of the neurobiological underpinnings of autism and fostering the development of targeted therapeutics that can improve the quality of life for autistic people.

References

Abi-Jaoude, E., Bhikram, T., Parveen, F., Levenbach, J., Lafreniere-Roula, M., & Sandor, P. (2022). A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. *Cannabis and Cannabinoid Research*, *(Abi-Jaoude E.) Department of Psychiatry, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada*. Medline. https://doi.org/10.1089/can.2022.0091

Aran, A., Cassuto, H., & Lubotzky, A. (2018). Cannabidiol based medical cannabis in children with autism-a retrospective feasibility study. *Neurology*, *90*(15). Embase. https://www.embase.com/search/results?subaction=viewrecord&id=L622309404&from=export

Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021). Cannabinoid treatment for autism: A proof-of-concept randomized trial. *Molecular Autism*, *12*(1), 6. https://doi.org/10.1186/s13229-021-00420-2

Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., Koren, G., & Berkovitch, M. (2019). Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities. *Frontiers in Pharmacology*, *9*, 1521.

Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. *Neuropsychopharmacology*, *36*(6), 1219–1226. https://doi.org/10.1038/npp.2011.6

Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello,
A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001). Molecular targets for
cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the
cellular uptake and enzymatic hydrolysis of anandamide: Cannabidiol, VR1 receptors
and anandamide inactivation. *British Journal of Pharmacology*, *134*(4), 845–852.
https://doi.org/10.1038/sj.bjp.0704327

Bottema-Beutel, K., Kapp, S. K., Lester, J. N., Sasson, N. J., & Hand, B. N. (2021). Avoiding
Ableist Language: Suggestions for Autism Researchers. *Autism in Adulthood*, *3*(1),
18–29. https://doi.org/10.1089/aut.2020.0014

Cairns, E. A., Benson, M. J., Bedoya-Pérez, M. A., Macphail, S. L., Mohan, A., Cohen, R.,
Sachdev, P. S., & McGregor, I. S. (2023). Medicinal cannabis for psychiatry-related
conditions: An overview of current Australian prescribing. *Frontiers in
Pharmacology*, *14*, 1142680. https://doi.org/10.3389/fphar.2023.1142680

Canitano, R., & Pallagrosi, M. (2017). Autism Spectrum Disorders and Schizophrenia
Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories.
Frontiers in Psychiatry, *8*, 69. https://doi.org/10.3389/fpsyt.2017.00069

Chin, R., Gil-Nagel, A., Mitchell, W., Patel, A. D., Perry, M. S., Weinstock, A., Checketts,
D., & Dunayevich, E. (2020). Long-term safety and efficacy of Cannabidiol (CBD)
treatment in Lennox Gastaut syndrome: Results overall and for patients completing 1-
3 years of an open-label extension (GWPCARE5). *European Journal of Neurology*,
27, 24.

Cochran, D. M., Sikoglu, E. M., Hodge, S. M., Edden, R. A. E., Foley, A., Kennedy, D. N.,
Moore, C. M., & Frazier, J. A. (2015). Relationship among Glutamine, γ-
Aminobutyric Acid, and Social Cognition in Autism Spectrum Disorders. *Journal of*

Child and Adolescent Psychopharmacology, *25*(4), 314–322.

https://doi.org/10.1089/cap.2014.0112

Cooper, R. E., Williams, E., Seegobin, S., Tye, C., & Asherson, P. (2016). The effects of

combined delta-9-tetrahydrocannabinol and cannabidiol on neurocognitive and

behavioural function in attention-deficit/hyperactivity disorder. *European*

Neuropsychopharmacology, *26*, S74.

Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-

Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Filho, A. S.,

Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., & Hallak, J. E.

C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized

social anxiety disorder: A preliminary report. *Journal of Psychopharmacology*, *25*(1),

121–130. https://doi.org/10.1177/0269881110379283

Efron, D., Freeman, J. L., Cranswick, N., Payne, J. M., Mulraney, M., Prakash, C., Lee, K. J.,

Taylor, K., & Williams, K. (2021). A pilot randomised placebo-controlled trial of

cannabidiol to reduce severe behavioural problems in children and adolescents with

intellectual disability. *British Journal of Clinical Pharmacology*, *87*(2), 436–446.

Ford, T. C., & Crewther, D. P. (2014). Factor Analysis Demonstrates a Common Schizoidal

Phenotype within Autistic and Schizotypal Tendency: Implications for

Neuroscientific Studies. *Frontiers in Psychiatry*, *5*.

https://doi.org/10.3389/fpsyt.2014.00117

Gaetz, W., Bloy, L., Wang, D. J., Port, R. G., Blaskey, L., Levy, S. E., & Roberts, T. P. L.

(2014). GABA estimation in the brains of children on the autism spectrum:

Measurement precision and regional cortical variation. *NeuroImage*, *86*, 1–9.

https://doi.org/10.1016/j.neuroimage.2013.05.068

Gao, R., & Penzes, P. (2015). Common Mechanisms of Excitatory and Inhibitory Imbalance

in Schizophrenia and Autism Spectrum Disorders. *Current Molecular Medicine*,

15(2), 146–167. https://doi.org/10.2174/1566524015666150303003028

Greenwood, L.-M., Leung, S., Michie, P. T., Green, A., Nathan, P. J., Fitzgerald, P.,

Johnston, P., Solowij, N., Kulkarni, J., & Croft, R. J. (2018). The effects of glycine on

auditory mismatch negativity in schizophrenia. *Schizophrenia Research*, *191*, 61–69.

https://doi.org/10.1016/j.schres.2017.05.031

Gunasekera, B., Davies, C., Martin-Santos, R., & Bhattacharyya, S. (2020). The Yin and

Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the

Differential Effects of Δ9-Tetrahydrocannabinol and Cannabidiol. *Biological

Psychiatry: Cognitive Neuroscience and Neuroimaging*, S2451902220303116.

https://doi.org/10.1016/j.bpsc.2020.10.007

Harada, M., Taki, M. M., Nose, A., Kubo, H., Mori, K., Nishitani, H., & Matsuda, T. (2011).

Non-Invasive Evaluation of the GABAergic/Glutamatergic System in Autistic

Patients Observed by MEGA-Editing Proton MR Spectroscopy Using a Clinical 3

Tesla Instrument. *Journal of Autism and Developmental Disorders*, *41*(4), 447–454.

https://doi.org/10.1007/s10803-010-1065-0

Hayes, S. A., & Watson, S. L. (2013). The Impact of Parenting Stress: A Meta-analysis of

Studies Comparing the Experience of Parenting Stress in Parents of Children With

and Without Autism Spectrum Disorder. *Journal of Autism and Developmental

Disorders*, *43*(3), 629–642. https://doi.org/10.1007/s10803-012-1604-y

Heussler, H., Cohen, J., Buchanan, C., O'Neill, C., Sebree, T., & O'Quinn, S. (2022). An

Open-Label, Tolerability and Efficacy Study of ZYN002 (cannabidiol) Administered

As A Transdermal Gel To Children And Adolescents With 22Q11.2 Deletion

Syndrome (INSPIRE). *Journal of Intellectual Disability Research*, *66*(8–9), 672.

Embase. https://doi.org/10.1111/jir.12962

Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016). Endocannabinoid signaling in social

functioning: An RDoC perspective. *Translational Psychiatry*, *6*(9), e905.

Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S.,

Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018). Plasma anandamide

concentrations are lower in children with autism spectrum disorder. *Molecular*

Autism, *9*, 18.

Kenny, L., Hattersley, C., Molins, B., Buckley, C., Povey, C., & Pellicano, E. (2016). Which

terms should be used to describe autism? Perspectives from the UK autism

community. *Autism*, *20*(4), 442–462. https://doi.org/10.1177/1362361315588200

Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015).

Cannabidiol is a negative allosteric modulator of the cannabinoid CB $_1$ receptor:

Negative allosteric modulation of CB $_1$ by cannabidiol. *British Journal of*

Pharmacology, *172*(20), 4790–4805. https://doi.org/10.1111/bph.13250

Larsen, C., & Shahinas, J. (2020). Dosage, Efficacy and Safety of Cannabidiol

Administration in Adults: A Systematic Review of Human Trials. *Journal of Clinical*

Medicine Research, *12*(3), 129–141. https://doi.org/10.14740/jocmr4090

Lattanzi, S., Brigo, F., Trinka, E., Zaccara, G., Cagnetti, C., Del Giovane, C., & Silvestrini,

M. (2018). Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and

Meta-Analysis. *Drugs*, *78*(17), 1791–1804.

Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter,

J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling

and alleviates psychotic symptoms of schizophrenia. *Translational Psychiatry*, *2*(3), e94–e94. https://doi.org/10.1038/tp.2012.15

Marsman, A., Mandl, R. C. W., Klomp, D. W. J., Cahn, W., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2017). Intelligence and Brain Efficiency: Investigating the Association between Working Memory Performance, Glutamate, and GABA. *Frontiers in Psychiatry*, *8*, 154. https://doi.org/10.3389/fpsyt.2017.00154

Narayan, A. J., Downey, L. A., Manning, B., & Hayley, A. C. (2022). Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance. *Neuroscience & Biobehavioral Reviews*, *143*, 104941. https://doi.org/10.1016/j.neubiorev.2022.104941

Nurmi, E. L., Spilman, S. L., Whelan, F., Scahill, L. L., Aman, M. G., McDougle, C. J., Arnold, L. E., H, en, B., Johnson, C., Sukhodolsky, D. G., Posey, D. J., Lecavalier, L., Stigler, K. A., Ritz, L., Tierney, E., Vitiello, B., & McCracken, J. T. (2013). Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. *Translational Psychiatry*, *3*, e274.

Parrella, N.-F., Hill, A. T., Enticott, P. G., Barhoun, P., Bower, I. S., & Ford, T. C. (2023). A systematic review of cannabidiol trials in neurodevelopmental disorders. *Pharmacology Biochemistry and Behavior*, *230*, 173607. https://doi.org/10.1016/j.pbb.2023.173607

Pinkham, A. E., Hopfinger, J. B., Pelphrey, K. A., Piven, J., & Penn, D. L. (2008). Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders. *Schizophrenia Research*, *99*(1–3), 164–175. https://doi.org/10.1016/j.schres.2007.10.024

Pretzsch, C. M., Floris, D. L., Voinescu, B., Elsahib, M., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Pretzsch, E., Williams, S., Murphy, D. G. M., Daly, E., & McAlonan, G. M. (2021). Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. *Molecular Autism*, *12*(1), 49. https://doi.org/10.1186/s13229-021-00454-6

Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Edden, R. A. E., Williams, S., Murphy, D. G. M., Daly, E., & McAlonan, G. M. (2019c). Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. *Neuropsychopharmacology*, *44*(8), 1398–1405. https://doi.org/10.1038/s41386-019-0333-8

Pretzsch, C. M., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Edden, R. A. E., Williams, S., Murphy, D. G. M., Daly, E., & McAlonan, G. M. (2019). Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): A single dose trial during magnetic resonance spectroscopy. *Translational Psychiatry*, *9*(1), 313. https://doi.org/10.1038/s41398-019-0654-8

Richdale, A. L., & Schreck, K. A. (2009). Sleep problems in autism spectrum disorders: Prevalence, nature, & possible biopsychosocial aetiologies. *Sleep Medicine Reviews*, *13*(6), 403–411. https://doi.org/10.1016/j.smrv.2009.02.003

Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid terpenoid entourage effects. *British Journal of Pharmacology*, *163*(7), 1344–1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x

Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2016). Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex—Possible involvement of 5-HT1A and CB1 receptors. *Behavioural Brain Research*, *303*, 218–227. https://doi.org/10.1016/j.bbr.2016.01.033

Shannon, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. *The Permanente Journal*. https://doi.org/10.7812/TPP/18-041

Sharma, A., & Shaw, S. R. (2012). Efficacy of Risperidone in Managing Maladaptive Behaviors for Children With Autistic Spectrum Disorder: A Meta-Analysis. *Journal of Pediatric Health Care*, *26*(4), 291–299. https://doi.org/10.1016/j.pedhc.2011.02.008

Silva Junior, E. A. D., Medeiros, W. M. B., Santos, J. P. M. D., Sousa, J. M. M. D., Costa, F. B. D., Pontes, K. M., Borges, T. C., Neto Segundo, C. E., Andrade E Silva, A. H., Nunes, E. L. G., Alves, N. T., Rosa, M. D. D., & Albuquerque, K. L. G. D. D. (2024). Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind, and placebo-controlled clinical trial. *Trends in Psychiatry and Psychotherapy*. https://doi.org/10.47626/2237-6089-2021-0396

Talantseva, O. I., Romanova, R. S., Shurdova, E. M., Dolgorukova, T. A., Sologub, P. S., Titova, O. S., Kleeva, D. F., & Grigorenko, E. L. (2023). The global prevalence of autism spectrum disorder: A three-level meta-analysis. *Frontiers in Psychiatry*, *14*, 1071181. https://doi.org/10.3389/fpsyt.2023.1071181

Tebartz van Elst, L., Maier, S., Fangmeier, T., Endres, D., Mueller, G. T., Nickel, K., Ebert,

D., Lange, T., Hennig, J., Biscaldi, M., Riedel, A., & Perlov, E. (2014). Disturbed

cingulate glutamate metabolism in adults with high-functioning autism spectrum

disorder: Evidence in support of the excitatory/inhibitory imbalance hypothesis.

Molecular Psychiatry, *19*(12), 1314–1325. https://doi.org/10.1038/mp.2014.62

Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R.,

Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., & Sommerville, K. (2018).

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome

(GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. *Lancet

(London, England)*, *391*(10125), 1085–1096.

Van Steensel, F. J. A., Bögels, S. M., & Perrin, S. (2011). Anxiety Disorders in Children and

Adolescents with Autistic Spectrum Disorders: A Meta-Analysis. *Clinical Child and

Family Psychology Review*, *14*(3), 302–317. https://doi.org/10.1007/s10567-011-

0097-0

VanDolah, H. J., Bauer, B. A., & Mauck, K. F. (2019). Clinicians' Guide to Cannabidiol and

Hemp Oils. *Mayo Clinic Proceedings*, *94*(9), 1840–1851.

https://doi.org/10.1016/j.mayocp.2019.01.003

Veenstra-VanderWeele, J., Cook, E. H., King, B. H., Zarevics, P., Cherubini, M., Walton-

Bowen, K., Bear, M. F., Wang, P. P., & Carpenter, R. L. (2017). Arbaclofen in

Children and Adolescents with Autism Spectrum Disorder: A Randomized,

Controlled, Phase 2 Trial. *Neuropsychopharmacology*, *42*(7), 1390–1398.

https://doi.org/10.1038/npp.2016.237

Warren, Z., McPheeters, M. L., Sathe, N., Foss-Feig, J. H., Glasser, A., & Veenstra-

VanderWeele, J. (2011). A Systematic Review of Early Intensive Intervention for

Autism Spectrum Disorders. *Pediatrics*, *127*(5), e1303–e1311.

https://doi.org/10.1542/peds.2011-0426

Wei, D., Dinh, D., Lee, D., Li, D., Anguren, A., Moreno-Sanz, G., Gall, C. M., & Piomelli, D. (2016). Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment. *Cannabis and Cannabinoid Research*, *1*(1), 81–89. https://doi.org/10.1089/can.2015.0008

Wei, D., Lee, D., Cox, C. D., Karsten, C. A., Peñagarikano, O., Geschwind, D. H., Gall, C. M., & Piomelli, D. (2015). Endocannabinoid signaling mediates oxytocin-driven social reward. *Proceedings of the National Academy of Sciences of the United States of America*, *112*(45), 14084–14089.

Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2008). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology*, *54*(1), 244–249.

https://doi.org/10.1016/j.neuropharm.2007.06.029

Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. *International Journal of Molecular Sciences*, *18*(9), 1916. https://doi.org/10.3390/ijms18091916